RxDoctor Payments Data

Jennifer Heaberlin, DO

Hematology & Oncology · Asheville, NCNPI 1841586856

Payments from drug & device makers

$72,395in general payments, 2019–2025

Across 368 payments — averaging $196.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$30K
  • Biontech SE$19K
  • AbbVie$12K
  • AstraZeneca$6K
  • Novartis$596
  • Pfizer$444
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$6,20299%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$72,395 in reported general payments places this provider in the 65th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$77,966
Medicare patients
290
Services billed
929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide85$1,124,777
IbrancePalbociclib51$816,033
JakafiRuxolitinib Phosphate45$796,639
XtandiEnzalutamide24$332,673
BrukinsaZanubrutinib21$279,750
RevlimidLenalidomide15$247,719
KisqaliRibociclib Succinate14$220,056
AlecensaAlectinib Hcl12$109,009
EliquisApixaban32$24,405
XareltoRivaroxaban29$23,689
Letrozole178$3,026
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen92$2,999
Tamoxifen Citrate112$1,984
Oxycodone Hcl85$1,359
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen47$1,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$444$840,43883 claims
Incyte CorporationJakafi$29,678$796,63945 claims
Astellas Pharma US IncXtandi$119$332,67324 claims
Beigene USA, Inc.Brukinsa$209$279,75021 claims
Bristol Myers SquibbRevlimid$409$247,71915 claims
NovartisKisqali$596$220,05614 claims
Genentech USA, Inc.Alecensa$310$109,00912 claims
Johnson & JohnsonXarelto$377$23,68929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →